| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 22.62 mm | 22.62 mm | 22.62 mm | 22.62 mm | 22.62 mm | 22.62 mm |
| Cash burn (monthly) | 3.09 mm | 596.75 k | 3.25 mm | 3.46 mm | 2.95 mm | 3.14 mm |
| Cash used (since last report) | 15.68 mm | 3.03 mm | 16.52 mm | 17.55 mm | 15.00 mm | 15.97 mm |
| Cash remaining | 6.94 mm | 19.59 mm | 6.11 mm | 5.07 mm | 7.62 mm | 6.65 mm |
| Runway (months of cash) | 2.2 | 32.8 | 1.9 | 1.5 | 2.6 | 2.1 |
| 13F holders | Current |
|---|---|
| Total holders | 16 |
| Opened positions | 2 |
| Closed positions | 12 |
| Increased positions | 2 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 1.59 bn |
| Total shares | 65.89 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| INVA Innoviva | 64.18 mm | $264.41 mm |
| Corvesta | 633.94 k | $202.00 k |
| Synthetic Genomics | 516.98 k | $2.19 mm |
| Vanguard | 225.29 k | $533.93 mm |
| Geode Capital Management | 107.07 k | $253.81 mm |
| Edgewood Management | 100.00 k | $237.00 mm |
| Renaissance Technologies | 46.50 k | $110.20 mm |
| SeaCrest Wealth Management | 34.95 k | $82.84 mm |
| BlackRock | 23.80 k | $56.41 mm |
| NTRS Northern Trust | 19.27 k | $45.68 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Feb 25 | Deborah Birx | Stock Options Common Stock | Grant | Acquire A | No | No | 2.04 | 240,000 | 489.60 k | 240,000 |
| 5 Feb 25 | Haimovitz Jules | Stock Options Common Stock | Grant | Acquire A | No | No | 2.04 | 54,343 | 110.86 k | 54,343 |
| 5 Feb 25 | David Duane House | Stock Options Common Stock | Grant | Acquire A | No | No | 2.04 | 25,000 | 51.00 k | 25,000 |
| 5 Feb 25 | Kramer Robin | Stock Options Common Stock | Grant | Acquire A | No | No | 2.04 | 54,343 | 110.86 k | 54,343 |
| 5 Feb 25 | Pierre Kyme | Stock Options Common Stock | Grant | Acquire A | No | No | 2.04 | 100,000 | 204.00 k | 100,000 |
